Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

Preclinical studies have demonstrated synergy between poly(ADP-ribose) polymerase (PARP) and phosphatidylinositol-3-kinase (PI3K)/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Discov
Autors principals: Yap, Timothy A., Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J., Lim, Joline S.J., Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C., Ruddle, Ruth, Raynaud, Florence I., Decordova, Shaun, Swales, Karen E., Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin P.O., Foxley, Andrew, Lord, Christopher J., Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S., Drew, Yvette, de Bono, Johann S.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611385/
https://ncbi.nlm.nih.gov/pubmed/32532747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0163
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars